BACKGROUND: Interleukin 10 (IL-10) exerts anti-inflammatory actions by counteracting many biological effects of interferon gamma (IFN-gamma). AIMS: To investigate this in humans, we studied the effects of human recombinant IL-10 administration on IFN-gamma production by patient leucocytes. Furthermore, we assessed the IFN-gamma inducible molecule neopterin and nitrite/nitrate serum levels, which are indicative of endogenous nitric oxide formation. METHODS: As part of two placebo controlled double blind studies, we analysed patients with chronic active Crohn's disease (CACD) who received eithersubcutaneous recombinant human IL-10 (n=44) or placebo (n=10) daily for 28 days, and patients with mild to moderate Crohn's disease (MCD) treated with eithersubcutaneous IL-10 (n=52) or placebo (n=16) daily for 28 days. Neopterin and nitrite/nitrate concentrations were measured in serum, and ex vivo IFN-gamma formation by lipopolysaccharide or phytohaemagglutinin (PHA) stimulated whole blood cells were investigated before, during, and after IL-10 therapy. RESULTS: In patients with CACD, the highest dose of 20 microg/kg IL-10 caused a significant increase in serum neopterin on days +15 and +29 of therapy compared with pretreatment levels. No changes were observed for nitrite/nitrate levels under either condition. In MCD, treatment with 20 microg/kg IL-10 resulted in a significant increase in PHA induced IFN-gamma production. CONCLUSIONS: High doses of IL-10 upregulate the production of IFN-gamma and neopterin. This phenomenon may be responsible for the lack of efficacy of high doses of IL-10 in the treatment of CACD and MCD.
RCT Entities:
BACKGROUND:Interleukin 10 (IL-10) exerts anti-inflammatory actions by counteracting many biological effects of interferon gamma (IFN-gamma). AIMS: To investigate this in humans, we studied the effects of human recombinant IL-10 administration on IFN-gamma production by patient leucocytes. Furthermore, we assessed the IFN-gamma inducible molecule neopterin and nitrite/nitrate serum levels, which are indicative of endogenous nitric oxide formation. METHODS: As part of two placebo controlled double blind studies, we analysed patients with chronic active Crohn's disease (CACD) who received either subcutaneous recombinant humanIL-10 (n=44) or placebo (n=10) daily for 28 days, and patients with mild to moderate Crohn's disease (MCD) treated with either subcutaneous IL-10 (n=52) or placebo (n=16) daily for 28 days. Neopterin and nitrite/nitrate concentrations were measured in serum, and ex vivo IFN-gamma formation by lipopolysaccharide or phytohaemagglutinin (PHA) stimulated whole blood cells were investigated before, during, and after IL-10 therapy. RESULTS: In patients with CACD, the highest dose of 20 microg/kg IL-10 caused a significant increase in serum neopterin on days +15 and +29 of therapy compared with pretreatment levels. No changes were observed for nitrite/nitrate levels under either condition. In MCD, treatment with 20 microg/kg IL-10 resulted in a significant increase in PHA induced IFN-gamma production. CONCLUSIONS: High doses of IL-10 upregulate the production of IFN-gamma and neopterin. This phenomenon may be responsible for the lack of efficacy of high doses of IL-10 in the treatment of CACD and MCD.
Authors: Y Shibata; L A Foster; M Kurimoto; H Okamura; R M Nakamura; K Kawajiri; J P Justice; M R Van Scott; Q N Myrvik; W J Metzger Journal: J Immunol Date: 1998-10-15 Impact factor: 5.422
Authors: S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer Journal: Gastroenterology Date: 2000-12 Impact factor: 22.682
Authors: R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan Journal: Gastroenterology Date: 2000-12 Impact factor: 22.682
Authors: G Weiss; H Schwaighofer; M Herold; D Nachbaur; H Wachter; D Niederwieser; E R Werner Journal: Transplantation Date: 1995-12-15 Impact factor: 4.939
Authors: Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou Journal: Cancer Res Date: 2011-11-28 Impact factor: 12.701
Authors: Jaime García de Tena; Luis Manzano; Juan Carlos Leal; Esther San Antonio; Verónica Sualdea; Melchor Alvarez-Mon Journal: J Clin Immunol Date: 2006-05-02 Impact factor: 8.317
Authors: S Melgar; M M-W Yeung; A Bas; G Forsberg; O Suhr; A Oberg; S Hammarstrom; A Danielsson; M-L Hammarstrom Journal: Clin Exp Immunol Date: 2003-10 Impact factor: 4.330
Authors: Kristine C Olson; Paige M Kulling Larkin; Rossana Signorelli; Cait E Hamele; Thomas L Olson; Mark R Conaway; David J Feith; Thomas P Loughran Journal: Cytokine Date: 2018-11-17 Impact factor: 3.861
Authors: Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm Journal: Oncoimmunology Date: 2016-06-27 Impact factor: 8.110